Timothy Brown, MD
Medical Oncology · Dallas, TXNPI 1790171239
Payments from drug & device makers
Across 53 payments — averaging $2472.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$70K
- Kyowa Kirin Co., Ltd$41K
- Incyte Corporation$18K
- Daiichi Sankyo Inc.$1K
- AstraZeneca$211
- Astellas Pharma US Inc$120
- plus $468 from 10 others
What the payments were for
- Consulting fees$4,38022%
- Speaking & faculty fees$12,65063%
- Travel & lodging$1,6688%
- Food & beverage$1,4127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 8 | $70,090 |
| Kyowa Kirin Co., Ltd | 1 | $40,839 |
| Incyte Corporation | 25 | $17,956 |
| Daiichi Sankyo Inc. | 1 | $1,355 |
| AstraZeneca | 2 | $211 |
| Astellas Pharma US Inc | 5 | $120 |
| Heron Therapeutics, Inc. | 1 | $119 |
| Johnson & Johnson | 1 | $83 |
| Zimmer Biomet | 1 | $64 |
| Janssen Research & Development, LLC | 1 | $57 |
| Exelixis Inc. | 2 | $38 |
| AVEO Pharmaceuticals, Inc. | 1 | $28 |
| Geron Corporation | 1 | $25 |
| Merck | 1 | $20 |
| Emmaus Medical, Inc. | 1 | $17 |
| Smith+Nephew | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$131,039 in reported general payments places this provider in the 55th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 13 | $878 |
| Prochlorperazine Maleate | 41 | $383 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 15 | $299 |
| Dexamethasone | 27 | $281 |
| Ondansetron Hcl | 49 | $230 |
| LoperamideLoperamide Hcl | 12 | $199 |
| Furosemide | 11 | $26 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Dallas
- Sawsan RashdanDallas$29.9M
- David GerberDallas$22.8M
- Joyce O'ShaughnessyDallas$20.8M
- Moshe LevyDallas$19.7M
- Minal BarveDallas$16.7M
- Andrew PaulsonDallas$11.5M
- Hans HammersDallas$11.4M
- James StraussDallas$9.1M
- Larry AndersonDallas$8.7M
- Heather McArthurDallas$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.